A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer

Inclusion Criteria:

* Patients must have biopsy proven endometrioid adenocarcinoma or adenosquamous carcinoma.
* Patients must have evidence of primary FIGO Stage III-IVB or recurrent endometrial cancer.
* Patients with non-measurable disease following complete cytoreduction at the time of initial operative management for Stage III-IVB are eligible.
* Patients with recurrent disease must have disease confirmed by one of the following:

  1. CT Scan
  2. MRI
  3. PET Scan
  4. Physical Exam
* Patients must have adequate organ function defined as:

  1. Platelets \>/= 100,000/1
  2. Granulocytes (ANC) \>/= 1,500/
  3. Creatinine \</= 1.6mg/dl
  4. SGOT (AST) \</= 3x upper limits of normal
  5. Bilirubin within institutional normal limits
* Patients must have adequate performance status (ECOG performance status 0-2.
* Patients must be age 19 or greater and have signed informed consent.

Exclusion Criteria:

* Patients with history of other malignancies (except non-melanoma skin cancer or carcinoma-in-situ of the cervix) are ineligible.
* Patients with high-risk histologic subtypes of endometrial cancer, namely papillary serous or clear cell histology are ineligible.
* Patients with evidence of uterine sarcoma, including leiomyosarcoma, carcinosarcoma, endometrial stromal sarcoma, and adenosarcoma are ineligible.
* Patients who are less than 8 weeks after the completion of radiotherapy are ineligible.
* Patients receiving any other investigational agents are ineligible.
* Patients with known hypersensitivity to paclitaxel, carboplatin, or megesterol are ineligible.
* Patients with uncontrolled current illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, serious peripheral neuropathy, or psychiatric illness/social situations that would limit or preclude compliance with study requirements are ineligible.